Israel
Every company in the roster headquartered in Israel.
Every company in the roster headquartered in Israel.
13 of 13 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Teva Pharmaceutical IndustriesTEVA · NYSE | 13 assets: 10 approved, 2 Ph 3, 1 Ph 1 | Dexmedetomidine (Igalmi)Phase 3 · SchizophreniaReliable signal | 15 Jan 2027Emrusolmin · Phase 1 | $49.8B | $4.1BSep 2026 | Cash-flow positive | $1.8B |
COMPUGEN LTDCGEN · Nasdaq | 3 assets: 1 Ph 3, 1 Ph 2, 1 Ph 1 | RilvegostomigPhase 3 · Non-Small Cell Lung Cancer | Mar 2027COM701 · Phase 1/2 | $185M | $100MDec 2025 | Cash-flow positive | $23M |
Enlivex TherapeuticsENLV · Nasdaq | 1 asset: 1 Ph 2 | AllocetraPhase 2 · Osteoarthritis | Feb 2027Allocetra · Phase 2 | $20M | $6.2MDec 2025 | Ended Aug 2026 | $9.2M |
Pluri Inc.PLUR · Nasdaq | 1 asset: 1 other | PLX-PADOsteoarthritis | None on record | $11M | $9.8MSep 2026 | ~2.0 qtrs | ~$25M |
BioLineRx Ltd.BLRX · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | $5.0M | $3.3MDec 2025 | Ended Oct 2026with a later raise | $8.1M |
Can-Fite BioPharmaCANF · Nasdaq | 2 assets: 2 Ph 3 | NamodenosonPhase 3 · Hepatocellular CarcinomaPartial signal | 31 Aug 2027Piclidenoson · Phase 2 | — | $8.5MDec 2025 | Ended Mar 2026 | $6.7M |
Galmed Pharmaceuticals Ltd.EOCN · Nasdaq | 1 asset: 1 Ph 3 | AramcholPhase 3 · MASH / NASH | None on record | — | $8.8MJun 2026 | ~3.2 qtrs | $5.6M |
KamadaKMDA · Nasdaq | 1 asset: 1 approved | Approved assets only | None on record | — | $75MDec 2025 | Cash-flow positive | $13M |
Lifeward Ltd.LFWD · Nasdaq | 1 asset: 1 Ph 3 | ORMD-0801Phase 3 · Type 2 DiabetesPartial signal | None on record | — | $5.0MSep 2026 | ~1.0 qtrs | $10M |
Kahr MedicalPrivate | 1 asset: 1 Ph 2 | DSP107Phase 2 · Colorectal Cancer | None on record | — | — | — | — |
Mapi PharmaPrivate | 1 asset: 1 Ph 2 | Cariprazine long-acting injection (Mapi Pharma)Phase 1/2 · Schizophrenia | 31 Dec 2026Cariprazine long-acting injection (Mapi Pharma) · Phase 1/2 | — | — | — | — |
Medison PharmaPrivate | 1 asset: 1 approved | Approved assets only | None on record | — | — | — | — |
Neurim Pharmaceuticals Ltd.Private | 1 asset: 1 Ph 3 | Melatonin prolonged-releasePhase 3 | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.